home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 09/24/19

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma

FLORHAM PARK, N.J., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the European Commission h...
CLRB - Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

Data presented at the 17th International Myeloma Workshop Patients in Cohort 6 achieved a meaningful clinical benefit with a 50% overall response rate and 100% disease control FLORHAM PARK, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a c...

CLRB - SDRL, MNK among premarket gainers

Mer Telemanagement Solutions (NASDAQ: MTSL ) +96%  on 1H results . More news on: Mer Telemanagement Solutions Ltd., Fibrocell Science, Inc., Cellectar Biosciences, Inc., Stocks on the move, Read more ...

CLRB - Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

FLORHAM PARK, N.J., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced an oral presentation at the up...
CLRB - Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

FLORHAM PARK, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a late-breaker poster presenta...

CLRB - Cellectar Appoints Dov Elefant as Chief Financial Officer

FLORHAM PARK, N.J., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Mr. Dov Elef...

CLRB - CLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study

FLORHAM PARK, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has successfully completed...
CLRB - Cellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

FLORHAM PARK, N.J., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the second qua...

CLRB - Two shops soften view on Pfizer in premarket analyst action

Cellectar Biosciences (NASDAQ: CLRB ) initiated with Buy rating and $6 (180% upside) price target at Brookline Capital. Shares up  8%  premarket. More news on: Cellectar Biosciences, Inc., Heat Biologics, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th...

CLRB - M&A dominate premarket gainers

Acacia Communications (NASDAQ: ACIA ) +37%  on being acquired by Cisco. More news on: Acacia Communications, Inc., Camber Energy, Inc., Check-Cap Ltd., Stocks on the move, Read more ...

Previous 10 Next 10